Treatment Options Available for Multiple Sclerosis
Managing Psychological Symptoms of Multiple Sclerosis
First Patient Enrolled in Ganaxolone Phase 3 Refractory Status Epilepticus Trial
The RAISE trial will examine the proportion of patients with refractory status epilepticus who experience status cessation within 30 minutes of initiation of intravenous ganaxolone.
CMSC Announces New Fall Dates & Location for its 2021 Annual Meeting
The annual meeting will now take place October 25–28, 2021 at the Rosen Shingle Creek in Orlando, Florida.
Cerebral Microhemorrhages Predict Faster Worsening on CDR-SB Score
Researchers compared CMH rates in PSEN1, PSEN2, and APP mutation carriers and noncarriers of dominantly inherited Alzheimer disease.
Areas of Need in Epilepsy Research: Barbara Jobst, MD
The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.
High Adherence With Integrated Sleep Practice-Supplied PAP Machines in Disturbed Sleep Breathing
Researchers also observed that PAP machines from ISPs were used for a longer median duration than those from DMEs.
FAME Study: Partial-Onset Seizures
Zolmitriptan Demonstrates Efficacy as Migraine Treatment in Post-Hoc Analysis
Observation of pain freedom at 30 minutes was more accurate than the observation of relief at 30 minutes in predicting pain freedom at 2 hours.
Raising the Importance of Deep Sleep in Cognitive Care: Christian Agudelo, MD
The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided thoughts on why cognitive care and sleep disorder care should crossover more often.
Videoconferencing for Preclinical Alzheimer Cognitive Composite Score is Accurate, Accessible
Researchers found that time between assessments was the only predictor of PACC score differences.
Blood-Based AlzoSure Biomarker Test Predicts Alzheimer Disease Prior to Symptom Onset
Earlier AD diagnosis with the AlzoSure assay could potentially make it feasible to initiate disease-modifying therapies much earlier in the disease process.
Supporting Patients With Parkinson Disease During COVID-19: James Beck, PhD
The chief scientific officer of the Parkinson’s Foundation discussed strategies to close the gap between household income and telehealth use.
Occlusion Site, Thrombus Length Are Good Predictors of ENDi in Minor Stroke, LVO
A score based on these variables was found to show good discrimination and calibration in predicting early neurological deterioration of ischemic origin, or ENDi.
Simufilam Improves Cognition, Behavior in Alzheimer Disease Open-Label Study
The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.
Psychological Impact of Multiple Sclerosis
AUPN Leadership Minute Episode 6: Chair Faculty Evaluations
Episode 6 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and David G Standaert, MD, PhD, of University of Alabama at Birmingham. [WATCH TIME: 4 minutes]
Parkinson Treatment Amantadine from Adamas Wins Second Indication
Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.
AASM’s Strong Recommendation for Cognitive Behavioral Therapy: Jennifer Martin, PhD
The AASM board of directors member and professor of medicine at UCLA discussed some strengths of CBT.
NeuroVoices: Barbara Karp, MD, and Sharon Meropol, MD, on NeuroCOVID Databank
Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.
VY-AADC Parkinson Disease Gene Therapy Program Terminated
Neurocrine Biosciences and Voyager Therapeutics have terminated the Parkinson disease portion of their partnership, ending development for VY-AADC, also known as NBIb-1817.
Accuracy of Prehospital Stroke Scales Identified
RACE, G-FAST, and CG-FAST were among the best performing prehospital stroke scales out of 8 scales tested and approached the performance of the clinician-assessed NIHSS.
Benefits to Data-Based Registries in ALS: James Berry, MD, MPH
The director of the Massachusetts General Hospital ALS Care Center spoke on the importance of data-based registries and how they can grow ALS research.
Low-Dose Rituximab Demonstrates Long-Term Benefit on Inflammatory MS Disease Activity
Treatment with low-dose protocol of rituximab is sufficient to maintain suppression of inflammatory disease activity in most patients with relapsing-remitting multiple sclerosis.
The Future of Managing Multiple Sclerosis
Atabecestat Associated With Cognitive Worsening in Alzheimer Disease
The results suggest that BACE-1 inhibitors, while a promising option to slow progression of Alzheimer disease, require further study with careful safety monitoring.
Treating Pediatric Migraine With Nerivio REN Device
After Theranica’s remote electrical neuromodulation was approved for those aged 12 years and older with migraine, study investigator Jennifer McVige, MD, MA, shared her insight.
Managing Parkinson Disease Despite Motor and Nonmotor Challenges: Stewart Factor, DO
The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine explained the various factors that make Parkinson so difficult to manage.
Fewer Lifetime AED Use Decreases Odds of Discontinuing Brivaracetam for Focal Seizures
Data suggest that treatment-emergent adverse events with adjunctive brivaracetam increased in incidence by number of lifetime AEDs.
FDA Approves Peginterferon Beta-1a Intramuscular Injection for Relapsing Multiple Sclerosis
The basis of the approval for peginterferon beta-1a was from a phase 1 crossover study that showed the drug’s bioequivalence to subcutaneous injection.
